Paper Details

  1. Home
  2. Paper Details

Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study.

Author: AnlaufMatthias, BroocksAndreas, HohagenFritz, KahlKai G, KochNicole, KordonAndreas, VielhaberKirsten, VoderholzerUlrich, WahlKarina, ZurowskiBartosz

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

While serotonin reuptake inhibitors (SRIs) help many people with obsessive-compulsive disorder (OCD), about 40-60% don't respond. This study examined the effectiveness of adding quetiapine to SRI treatment for severe OCD in adults.
Paper Details　
Original Abstract of the Article :
Although many patients with obsessive-compulsive disorder (OCD) benefit from treatment with serotonin reuptake inhibitors (SRIs), it is estimated that 40% to 60% of them do not respond. The objective of the present study was to evaluate the efficacy of quetiapine added to baseline treatment with SRI...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/18794652

データ提供：米国国立医学図書館（NLM）

Quetiapine for Obsessive-Compulsive Disorder: A New Hope in the Desert?

The world of mental health research is like a vast desert, with many mysteries waiting to be uncovered. One such mystery is the treatment of obsessive-compulsive disorder (OCD), a condition that can be as relentless as a desert sandstorm. While serotonin reuptake inhibitors (SRIs) are a common treatment, they don’t always work for everyone. This study delves into the potential of quetiapine as an additional treatment for those who don’t respond to SRIs. The study was conducted using a double-blind, randomized, placebo-controlled design, a rigorous approach that ensures the results are as reliable as an oasis in the desert. The researchers discovered that adding quetiapine to SRI treatment may be beneficial in treating severe OCD, providing a glimmer of hope for individuals struggling with this challenging condition.

A Glimmer of Hope in the Desert

This research suggests that adding quetiapine to existing SRI treatment could be a valuable strategy for managing severe OCD. Imagine a traveler in the desert, exhausted and thirsty, who stumbles upon a small spring that offers some relief. This is what quetiapine may provide for those who have found limited success with SRIs alone. The research showed that quetiapine, when used in conjunction with SRIs, may improve the symptoms of OCD in a significant portion of individuals who have not responded to SRIs alone.

Navigating the Desert of OCD: Practical Implications

This study provides valuable insights into the potential benefits of quetiapine in treating severe OCD. If you are struggling with OCD and haven’t found relief with SRIs alone, it may be worth discussing this treatment option with your doctor. Remember, navigating the desert of OCD can be challenging, but with the right resources and guidance, you can find your own oasis of hope.

Dr. Camel's Conclusion

This research offers a promising new avenue for treating severe OCD, reminding us that even in the vast desert of mental health, there are always new discoveries to be made.

Date :
  1. Date Completed 2008-11-24
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

18794652

DOI: Digital Object Identifier

00004714-200810000-00013

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.